This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oramed Pharmaceuticals Inc. (OTCBB: ORMP) (
www.oramed.com), a developer of oral drug delivery systems, announced today that its work entitled "Decreased CRP levels in response to a six-week, once-daily oral insulin regimen" will be presented at the XVI International Symposium on Atherosclerosis (ISA2012) on March 25-29, 2012, to be held in Sydney, Australia.
"The selection of Oramed as one of the companies to present at the ISA2012 is a great opportunity for us to apprise the scientific community of the important progress we have made," said Dr. Miriam Kidron, Oramed's Chief Scientific Officer.
Oramed's poster will be presented on March 26, 2012, during poster session #1.
For more information about the conference, please visit
For more information about Oramed Pharmaceuticals, please visit
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed is seeking to revolutionize the treatment of diabetes through its patented flagship product, an orally ingestible insulin capsule, currently in phase 2 clinical trials. Established in 2006, Oramed's technology is based on over 25 years of research by top research scientists at Jerusalem's Hadassah Medical Center. The Company's corporate and R&D headquarters are based in Jerusalem.
For more information, please visit www.oramed.comForward-looking statements
Some of the statements contained in this press release are forward-looking statements which involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the company or industry results to be materially different from any future results, performance, or achievements expressed or implied by such forward- looking statements. Included here are the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for our product candidates; competition from other pharmaceutical or biotechnology companies; and the company's ability to obtain additional funding required to conduct its research, development and commercialization activities. Please refer to the company's filings with the Securities and Exchange Commission for a comprehensive list of risk factors that could cause actual results, performance or achievements of the company to differ materially from those expressed or implied in such forward-looking statements. The company undertakes no obligation to update or revise any forward-looking statements.